[Heart, diabetes and glitazones].
Beneficial metabolic effects of rosiglitazone are now well established and its adverse events, generally minor or mild well known too. Following a brief review of these metabolic effects and main adverse events, we mainly describe fluid retention (and edema) and the heart failure risk, their risk factors, clinical and diagnosis characteristics, possible pathophysiological mechanisms and the main preventive measures are reviewed. Numerous experimental data and/or preliminary studies in type 2 diabetic patients, including effects on cardiovascular risk factors or markers, justify to conduct a large prospective long term clinical program to assess rosiglitazone effects on cardiovascular morbidity and mortality in type 2 diabetic patients at high cardiovascular risk, these studies are briefly described.
Le Feuvre
C
C
Institut de Cardiologie, CHU Pitié-Salpêtrière, F-75651 Paris Cedex 13. claude.lefeuvre@psl.ap-hop-paris.fr
D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology*; D004487:Edema / Q000139:chemically induced; D006321:Heart / Q000503:physiopathology*; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone